Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5711-4. doi: 10.1016/j.bmcl.2011.08.032. Epub 2011 Aug 11.

Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.

Author information

1
Pharmacology and Toxicology, RTI International, 3040 Cornwallis Rd., Research Triangle Park, NC 27709-2194, USA.

Abstract

CB1 receptor antagonists that are peripherally restricted were targeted. Compounds with permanent charge as well as compounds that have increased polar surface area were made and tested against CB1 for binding and activity. Sulfonamide and sulfamide with high polar surface area and good activity at CB1 were rationally designed and pharmacologically tested. Further optimization of these compounds and testing could lead to the development of a new class of therapeutics to treat disorders where the CB1 receptor system has been implicated.

PMID:
21875798
PMCID:
PMC3171605
DOI:
10.1016/j.bmcl.2011.08.032
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center